Ownership research and analyst forecasts provide insights into stock opportunities. Institutional investors own 51% of Cytek Biosciences, impacting its market moves. Top shareholders include BlackRock, Brown Capital Management, and The Vanguard Group. Insider ownership and public and private equity stakes also influence company decisions.